Background: The high mutation burden of triple-negative breast cancer (TNBC) is related to its
immunogenic potential. The presence of tumour infiltrating lymphocytes (TILs) in the
preclinical stage of disease reflects a proinflammatory immune response against cancer
cells. However, cancer cells may modulate it to support tumour growth and progression.
A chaperone HSP70 molecule expression, upregulated by oncogenic signalling, supports
the formation of early-stage breast cancer (BC) as well. Moreover, in the later course
of the disease, HSP70 is actively released by the cancer cells and can induce the
termination of the specific immune response. The aim of this study was to explore
the role and possible predictive value of the HSP70(+) immune cells in a deep layer
(HSP70-IC-DL) of TNBC.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to European Journal of CancerAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
Article info
Identification
Copyright
© 2022 Elsevier Ltd. All rights reserved. Published by Elsevier Inc. All rights reserved.
